Sei Investments Co. Has $47.12 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

Sei Investments Co. increased its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 1.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,207,060 shares of the company's stock after purchasing an additional 20,802 shares during the quarter. Sei Investments Co. owned approximately 0.12% of Kenvue worth $47,121,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mizuho Securities USA LLC grew its position in shares of Kenvue by 46.3% during the 4th quarter. Mizuho Securities USA LLC now owns 181,712 shares of the company's stock worth $3,880,000 after buying an additional 57,524 shares during the period. Virtu Financial LLC bought a new position in Kenvue in the fourth quarter valued at approximately $1,269,000. Millstone Evans Group LLC bought a new position in Kenvue in the fourth quarter valued at approximately $565,000. TD Private Client Wealth LLC grew its holdings in Kenvue by 116.6% during the 4th quarter. TD Private Client Wealth LLC now owns 279,728 shares of the company's stock worth $5,972,000 after acquiring an additional 150,601 shares during the period. Finally, Berkeley Capital Partners LLC raised its position in shares of Kenvue by 1.2% during the 4th quarter. Berkeley Capital Partners LLC now owns 69,250 shares of the company's stock valued at $1,478,000 after acquiring an additional 816 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Up 0.5 %

Shares of KVUE stock traded up $0.12 on Thursday, hitting $23.52. 13,790,573 shares of the stock were exchanged, compared to its average volume of 16,136,490. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $44.95 billion, a P/E ratio of 44.38, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The business has a 50-day moving average of $22.22 and a 200 day moving average of $22.45.

Remove Ads

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.49%. Kenvue's dividend payout ratio is 154.72%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on KVUE. UBS Group reduced their price target on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada restated a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Canaccord Genuity Group upped their price target on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Piper Sandler upped their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a "buy" rating to a "hold" rating and decreased their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $24.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.